1. Home
  2. VTEX vs CTMX Comparison

VTEX vs CTMX Comparison

Compare VTEX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VTEX

VTEX

VTEX

HOLD

Current Price

$3.65

Market Cap

561.5M

Sector

Technology

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$5.06

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTEX
CTMX
Founded
1999
2008
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
561.5M
596.2M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
VTEX
CTMX
Price
$3.65
$5.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$6.16
$8.86
AVG Volume (30 Days)
1.1M
2.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$138,103,000.00
Revenue This Year
$8.28
N/A
Revenue Next Year
$10.36
N/A
P/E Ratio
$43.33
$22.58
Revenue Growth
N/A
36.45
52 Week Low
$2.84
$0.40
52 Week High
$6.82
$6.35

Technical Indicators

Market Signals
Indicator
VTEX
CTMX
Relative Strength Index (RSI) 67.05 44.70
Support Level $2.92 $3.83
Resistance Level $3.84 $6.20
Average True Range (ATR) 0.16 0.33
MACD 0.09 -0.10
Stochastic Oscillator 94.67 16.54

Price Performance

Historical Comparison
VTEX
CTMX

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: